Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Epalrestat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 known ✓ | P15121 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 11/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | NPC1 | O15118 | 3/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 1/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | AKR1B10 | O60218 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | DRD2 | P14416 | 1/20 | 1.00 |
| ▸ | AKR1A1 | P14550 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Epalrestat SCHEMBL17223887 | 1.00 | MAPT (1.00) | MAPTLMNANPC1AKR1B1ABCC3 | |
| Epalrestat SCHEMBL6679566 | 1.00 | MAPT (1.00) | MAPTLMNANPC1AKR1B1ABCC3 | |
| Epalrestat SCHEMBL49049 | 1.00 | MAPT (1.00) | MAPTLMNANPC1AKR1B1ABCC3 | |
| Epalrestat SCHEMBL49048 | 1.00 | MAPT (1.00) | MAPTLMNANPC1AKR1B1ABCC3 | |
| Epalrestat SCHEMBL27969659 | 0.99 | MAPT (0.98) | MAPTLMNANPC1AKR1B1ABCC3 | |
| Epalrestat SCHEMBL27969660 | 0.99 | MAPT (0.98) | MAPTLMNANPC1AKR1B1ABCC3 | |
| Epalrestat SCHEMBL29229735 | 0.99 | MAPT (0.98) | MAPTLMNANPC1AKR1B1ABCC3 | |
| Epalrestat SCHEMBL28070020 | 0.99 | MAPT (0.98) | MAPTLMNANPC1AKR1B1ABCC3 | |
| Epalrestat SCHEMBL1331526 | 0.99 | MAPT (0.98) | MAPTLMNANPC1AKR1B1ABCC3 | |
| Epalrestat SCHEMBL27969621 | 0.99 | MAPT (0.98) | MAPTLMNANPC1AKR1B1ABCC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026100969-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING SARCOPENIA | 아주대학교 산학협력단 | 2026-05-15 | — | — | WO | claimed |
| WO-2026100969-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING SARCOPENIA | 아주대학교 산학협력단 | 2026-05-15 | — | — | WO | disclosed |
| WO-2026100969-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING SARCOPENIA | 아주대학교 산학협력단 | 2026-05-15 | — | — | WO | disclosed |
| US-20250223262-A1 | SYNTHESIS OF MORPHINANS WITH REDUCED HERG ACTIVITY AND MOP BINDING | TAROS CHEMICALS GMBH & CO. KG (DE) | 2025-07-10 | — | — | US | disclosed |
| CN-120189426-A | Application of mizoribine in preparation of preparation for inhibiting influenza virus | 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） | 2025-06-24 | — | — | CN | disclosed |
| CN-120131690-A | Application of buconazole in preparation of preparation for inhibiting influenza virus | 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） | 2025-06-13 | — | — | CN | disclosed |
| CN-120131649-A | Application of wocelotor in preparation of preparation for inhibiting influenza virus | 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） | 2025-06-13 | — | — | CN | disclosed |
| CN-119950504-A | Application of epalrestat in preparation of preparation for inhibiting influenza virus | 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） | 2025-05-09 | — | — | CN | disclosed |
| CN-119950522-A | Application of triptolide in preparation of preparation for inhibiting influenza virus | 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） | 2025-05-09 | — | — | CN | disclosed |
| CN-119859128-A | Refining method and application of high-purity epalrestat | 沈阳永大制药股份有限公司 | 2025-04-22 | — | — | CN | disclosed |
| JP-2004210702-A | NEW CRYSTAL OF 5-[(1Z,2E)-2-METHYL-3-PHENYL-2-PROPENYLIDENE]-4-OXO-2-THIOXO-3-THIAZOLIDINEACETIC ACID, METHOD FOR PRODUCING THE SAME, AND PHARMACEUTICAL WITH THE SAME AS ACTIVE INGREDIENT | ONO PHARMACEUT CO LTD | 2004-07-29 | — | — | JP | disclosed |
| JP-2004210766-A | METHOD FOR PRODUCING NEW CRYSTAL OF 5-[(1Z,2E)-2-METHYL-3-PHENYL-2-PROPENYLIDENE]-4-OXO-2-THIOXO-3-THIAZOLIDINEACETIC ACID | ONO PHARMACEUT CO LTD | 2004-07-29 | — | — | JP | disclosed |
| JP-2004210766-A | METHOD FOR PRODUCING NEW CRYSTAL OF 5-[(1Z,2E)-2-METHYL-3-PHENYL-2-PROPENYLIDENE]-4-OXO-2-THIOXO-3-THIAZOLIDINEACETIC ACID | ONO PHARMACEUT CO LTD | 2004-07-29 | — | — | JP | disclosed |
| JP-2004210775-A | METHOD FOR PRODUCING CRYSTAL OF 5-[(1Z,2E)-2-METHYL-3-PHENYL-2-PROPENYLIDENE]-4-OXO-2-THIOXO-3-THIAZOLIDINEACETIC ACID | ONO PHARMACEUT CO LTD | 2004-07-29 | — | — | JP | disclosed |
| JP-2004210775-A | METHOD FOR PRODUCING CRYSTAL OF 5-[(1Z,2E)-2-METHYL-3-PHENYL-2-PROPENYLIDENE]-4-OXO-2-THIOXO-3-THIAZOLIDINEACETIC ACID | ONO PHARMACEUT CO LTD | 2004-07-29 | — | — | JP | disclosed |
| US-20040002526-A1 | Phospholipase D inhibitors and uses thereof | CELL THERAPEUTICS, INC. | 2004-01-01 | — | — | US | disclosed |
| US-20020198201-A1 | Combination of a PTPase inhibitor and an aldose reductase inhibitor | WYETH | 2002-12-26 | — | — | US | disclosed |
| WO-2002098510-A1 | COMBINATION OF A PTPASE INHIBITOR AND AN ALDOSE REDUCTASE INHIBITOR | WYETH (US) | 2002-12-12 | — | — | WO | disclosed |
| US-5155125-A | Orally Administering; having an aldose reductase inhibitory activity | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 1992-10-13 | — | — | US | disclosed |
| EP-0437025-A2 | Compositions containing aldose reductase inhibitors for the treatment of ulcers | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 1991-07-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002526-A1 | Phospholipase D inhibitors and uses thereof | PLD2, PLD1, PLA2G2D | AKR1B1 1614/4885MAPT 4292/4885LMNA 2840/4885 |
| US-20250223262-A1 | SYNTHESIS OF MORPHINANS WITH REDUCED HERG ACTIVITY AND MOP BINDING | OPRM1, TRPM5, TRPM7 | AKR1B1 1603/4885MAPT 2287/4885LMNA 579/4885 |
| US-20020198201-A1 | Combination of a PTPase inhibitor and an aldose reductase inhibitor | PTPMT1, LPL, PTPRE | AKR1B1 49/4885MAPT 233/4885LMNA 2843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.